来那度胺联合地塞米松治疗多发性骨髓瘤性胸腔积液。
Pomalidomide and dexamethasone in myelomatous pleural effusion.
机构信息
Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA
Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA.
出版信息
BMJ Case Rep. 2020 Dec 10;13(12):e235899. doi: 10.1136/bcr-2020-235899.
Abstract
Myelomatous pleural effusion (MPE) is an uncommon clinical entity and occurs in less than 1% of all patients with multiple myeloma. MPE indicates a progression of disease, therefore is associated with a poor prognosis and estimated median survival of <3 months. Treatment of MPE is challenging, and the data regarding the role of novel agents lack in the literature. Herein, we report a relapsed IgA myeloma case of a patient presenting with MPE, who was treated with pomalidomide with a very good partial response.
摘要
浆细胞瘤性胸腔积液（MPE）是一种罕见的临床病症，不到所有多发性骨髓瘤患者的 1%会发生这种情况。MPE 表明疾病进展，因此与预后不良相关，估计中位生存期<3 个月。MPE 的治疗具有挑战性，并且文献中缺乏关于新型药物作用的数据。在此，我们报告了一例复发的 IgA 骨髓瘤病例，该患者表现为 MPE，接受了泊马度胺治疗，获得了非常好的部分缓解。
相似文献
1
Pomalidomide and dexamethasone in myelomatous pleural effusion.来那度胺联合地塞米松治疗多发性骨髓瘤性胸腔积液。
BMJ Case Rep. 2020 Dec 10;13(12):e235899. doi: 10.1136/bcr-2020-235899.
2
Multiple myeloma with myelomatous pleural effusion: a case report and review of the literature.多发性骨髓瘤伴骨髓瘤性胸腔积液：一例病例报告及文献复习
Acta Haematol. 2008;120(2):108-11. doi: 10.1159/000165694. Epub 2008 Oct 29.
3
Concurrent Myelomatous Pleural Effusion and Extramedullary Mediastinal Involvement as an Initial Manifestation of Multiple Myeloma.并发骨髓瘤性胸腔积液和髓外纵隔受累作为多发性骨髓瘤的初始表现
Am J Case Rep. 2016 Jul 11;17:472-5. doi: 10.12659/ajcr.898849.
4
Myelomatous pleural effusion in multiple myeloma- A rare presentation.多发性骨髓瘤中的浆膜腔多发性骨髓瘤-一种罕见的表现。
J Cancer Res Ther. 2024 Jan 1;20(1):476-478. doi: 10.4103/jcrt.jcrt_1772_22. Epub 2023 May 2.
5
Extramedullary Multiple Myeloma With Pleural Involvement: A Rare Clinical Entity.伴有胸膜受累的髓外多发性骨髓瘤：一种罕见的临床实体。
Arch Bronconeumol (Engl Ed). 2019 Jun;55(6):333-334. doi: 10.1016/j.arbres.2018.08.011. Epub 2018 Oct 22.
6
Myelomatous pleural effusion: a case series in a single institution and literature review.骨髓瘤性胸腔积液：单机构病例系列及文献综述
Korean J Lab Med. 2011 Oct;31(4):225-30. doi: 10.3343/kjlm.2011.31.4.225. Epub 2011 Oct 3.
7
Pleural Effusion in Multiple Myeloma.多发性骨髓瘤中的胸腔积液
Intern Med. 2016;55(4):339-45. doi: 10.2169/internalmedicine.55.4733. Epub 2016 Feb 15.
8
Pleural effusion formation in the course of myeloma.
Arch Bronconeumol. 2015 Aug;51(8):418-9. doi: 10.1016/j.arbres.2014.05.009. Epub 2015 Jan 23.
9
Unilateral pleural effusion as a presenting manifestation of plasma cell myeloma (multiple myeloma): a case report.单侧胸腔积液作为浆细胞骨髓瘤（多发性骨髓瘤）的首发表现：一例报告
Acta Cytol. 2010 Sep-Oct;54(5 Suppl):780-2.
10
Myelomatous pleural effusion.骨髓瘤性胸腔积液
J Assoc Physicians India. 2006 Sep;54:738-9.
本文引用的文献
1
Development of CAR-T cell therapies for multiple myeloma.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤的研究进展。
Leukemia. 2020 Sep;34(9):2317-2332. doi: 10.1038/s41375-020-0930-x. Epub 2020 Jun 22.
2
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.达雷妥尤单抗联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤：随机、开放标签、3 期 POLLUX 研究的扩展随访。
Leukemia. 2020 Jul;34(7):1875-1884. doi: 10.1038/s41375-020-0711-6. Epub 2020 Jan 30.
3
Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.基于泊马度胺的方案治疗复发和复发/难治性多发性骨髓瘤：2 期和 3 期临床试验的系统评价和荟萃分析。
Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):447-461. doi: 10.1016/j.clml.2019.04.003. Epub 2019 Apr 6.
4
Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature.多发性骨髓瘤性胸腔积液的临床病理特征：单中心真实世界经验及文献复习。
Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):183-189.e1. doi: 10.1016/j.clml.2018.12.003. Epub 2019 Jan 3.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
7
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.达雷妥尤单抗耐药在晚期多发性骨髓瘤患者中很常见，与 CD38 表达无关，与预后不良有关。
Eur J Haematol. 2018 May;100(5):494-501. doi: 10.1111/ejh.13046. Epub 2018 Mar 25.
8
Cytology and clinical features of myelomatous pleural effusion: Three case reports and a review of the literature.骨髓瘤性胸腔积液的细胞学及临床特征：三例报告并文献复习
Diagn Cytopathol. 2018 Jul;46(7):604-609. doi: 10.1002/dc.23894. Epub 2018 Feb 5.
9
Characteristics of patients with myelomatous pleural effusion. A systematic review.骨髓瘤性胸腔积液患者的特征。一项系统评价。
Rev Clin Esp (Barc). 2018 Mar;218(2):89-97. doi: 10.1016/j.rce.2017.11.001. Epub 2017 Nov 29.
10
Pleural Effusion in Multiple Myeloma: Characteristics and Practice Patterns.多发性骨髓瘤中的胸腔积液：特征与实践模式
Acta Haematol. 2017;138(2):69-76. doi: 10.1159/000477793. Epub 2017 Aug 11.
Zotero 插件